Founded in Madison, United States, BrainXell focuses on providing high-purity, induced pluripotent stem cell (iPSC)-derived human neurons for research and development, particularly in drug discovery. The company's core mission is to advance neurological research by offering reliable and scalable neuron cultures that are disease-relevant and easy to use. Their product line includes reproducible neuron cultures with fast maturation times and the ability to produce large batches, along with custom services tailored to specific project needs.

BrainXell has garnered attention for its innovative approach to creating high-quality neuron cultures, which has significant implications for the field of drug discovery. The company collaborates with leading researchers and institutions to further its mission. Notable achievements include the successful commercialization of their neuron cultures and bespoke services, which have been widely adopted in both academic and pharmaceutical research settings. BrainXell's impact lies in its contribution to more efficient and effective neurological research, potentially accelerating the development of new treatments for various brain disorders.